BIOMIMESYS® 3D technology is a natural HA-based scaffold to better mimic the tissue microenvironment and provide more predictive tools for drug development. The BIOMIMESYS® products are formed by crosslinking reaction of hydrosoluble modified hyaluronic acid and others matrix components with ADH (adipic acid dihydrazide), to mimic the extracellular matrix (ECM). Depending on the organ, ECM components vary and are present in different proportions, allowing a more or less dense and compact cellular environment. BIOMIMESYS® 3D technology allows us to reproduce the cell microenvironment of each organ.
Click here to get more information!
To ensure personalised treatment for familial hypercholesterolemia
To develop relevant 3D models of different tumors, in order to better assess the efficiency of anticancer therapies.
A holistic approach to address brain delivery
Face to the high failure of drug candidate in clinical trial, in particular involving the brain, we goal to develop more relevant and more predictive in vitro models for preclinical assessment, in the aim to early select molecules of interest, in term of efficacy and safety.
To design and industrialize new pharmacological in vitro assays for the screening of compounds/biopharmaceuticals in 3D
To develop the technological platform to produce lab-grown meats. The project is funded by EUREKA and the national funding agencies associated with the Eurostars program.
To develop a universal “plug-and-play” liver-on-chip platform mimicking the major events occurring in the liver sinusoid in order to predict the hepatoxicity of drugs.
To explore the use of AI technologies to improve different steps of 3D biological picture exploitation
In this presentation, Nathalie MAUBON (CEO HCS Pharma), give an overview of drugs discovery, from pre-19th century are, where trials are done on humans, to nowadays where clinical trials are safer but with a dramatic Read more…
From different studies we know that more than 92% of drug candidates for Central Nervous System diseases fail in clinical trials, with 34% of safety failure. All that candidates have successfully passed in vitro steps Read more…
Our project director Elodie is participating to EUSAAT congress in Linz (Austria) this week, the European Congress on Alternatives to Animal Testing. She will have the pleasure to present our work aiming at bridging the Read more…
Presentation in english Environ 90 % des candidats médicaments échouent aux essais cliniques, notamment en neurologie, faute d’efficacité. Cela met en évidence un manque de pertinence dans les modèles précliniques, y compris les modèles in Read more…
Présentation en français About 90% of drug-candidates failed in clinical trials, in particular in neurology, due to a lack of efficacy. That highlights a lack of relevance in preclinical models, including in vitro models, which Read more…
When Tuesday, October 4, 2022 – 9AM (CEST) / 3PM (CST) / 4PM (JST) / 3AM (EST) Thursday, October 6, 2022 – 1:30PM (CEST) / 7:30PM (CST) / 8:30PM (JST) / 7:30AM (EST) Where Online, Read more…
Next month, we will have the pleasure to participate in the 23rd EUSAAT (EUropean Society for Alternative to Animal Testing) congress, which will take place in Linz (Austria) on the 26th-28th of September. We have Read more…
There are several products today for 3D cell culture and many could be considered as “hydrogels”. In this short article, we explain differences between BIOMIMESYS® and hydrogels to help you to choose the right product Read more…
HCS Pharma est une start-up biotechnologie créée en 2014, installée au Biocentre Fleming (derrière le CHR et le parc Eurasanté, à Loos). Dans le cadre de son développement commercial, HCS Pharma recherche un(e) étudiant(e) en Read more…
HCS Pharma est une start-up biotechnologie créée en 2014, installée au Biocentre Fleming (derrière le CHR et le parc Eurasanté, à Loos). Dans le cadre de son développement commercial, HCS Pharma recherche un(e) étudiant(e) en Read more…
The Federation of European Neuroscience Societies (FENS) forum 2022 took place in Paris, from 9 to 15 July. This event gathers nearly 8,000 neuroscientists from 92 countries. Twenty-two plenary and special lectures were given in Read more…
Alejandra is a pharmacist graduated from University Católica de Santa María, Arequipa – Peru. She obtained her PhD in Biomolecules, pharmacology and therapeutics at the University of Lille in 2018. During her doctoral formation, Alejandra Read more…
We are very pleased to talk with Pr Robert-Alain Toillon from University of Lille about his uses of BIOMIMESYS® technology in oncology and more specificaly on breast cancer. English is below Je m’appelle Robert-Alain Toillon Read more…
We are please to announce our CEO, Nathalie Maubon, joined the advisory board of PharmaIQ, the leading network of professionals in pharmaceutical industry. PharmaIQ is an active community of more than 125.000 people, sharing their Read more…
We previously showed that human pluripotent stem cells (hiPSCs) provide a suitable model to studymetabolic diseases upon hepatocyte-like cell (HLC) differentiation. With a non-invasive approach, hiPSCs can be generated from urine samples of patients and Read more…
HCS Pharma – Siège de Lille
Biocentre Fleming Bat A
250 rue Salvador Allende
59120 LOOS
See on map
+33 769 999 137
Only for customers please, if you have another interest use the form contact.
